imfinzi
astrazeneca ab - durvalumab - carcinoma, pulmón no microcítico - agentes antineoplásicos - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).
imfinzi® 50 mg/ml concentrado para solución para perfusión
astrazeneca peru s.a. - droguerÍa - durvalumab - concentrado para solución para perfusión - 50 mg/ml - por mililitro 1.00 - - durvalumab
imfinzi concentrado para solución para perfusión 120 mg/2,4 ml (durvalumab)
astrazeneca s.a. - durvalumab - sin formulas
imfinzi concentrado para solución para perfusión 500 mg/10 ml (durvalumab)
astrazeneca s.a. - durvalumab - sin formulas
imjudo
astrazeneca ab - tremelimumab - carcinoma, hepatocellular - agentes antineoplásicos - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.
tremelimumab astrazeneca
astrazeneca ab - tremelimumab - carcinoma, pulmón no microcítico - agentes antineoplásicos - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.
imfinzi ®
astrazeneca ab suecia - durvalumab 50mg/ml - concentrado para solucion para perfusion - durvalumab 50mg/ml
imfinzi® 50 mg/ml concentrado para solución para perfusión
durvalumab - concentrado para solución para perfusión - 50 mg/ml
imfinzi 50 mg/ml polvo per a perfusió 1 vial 2,4 ml
imfinzi 50 mg/ml polvo per a perfusió 1 vial 10 ml